Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.77 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.77 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.71 |
| ▸ | TNKS | O95271 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.71 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.71 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.71 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.71 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.71 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.71 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.71 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.71 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.71 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.71 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.71 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.71 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17961748 | 0.93 | PARP1 (0.75) | PARP1PARP2PARP3TNKSADORA1 | |
| SCHEMBL30332603 | 0.91 | PARP1 (0.79) | PARP1PARP2PARP3TNKSADORA1 | |
| SCHEMBL16571836 | 0.90 | PARP1 (0.79) | PARP1PARP2PARP3TNKSADORA1 | |
| SCHEMBL16571622 | 0.89 | PARP1 (0.78) | PARP1PARP2PARP3TNKSADORA1 | |
| SCHEMBL16571625 | 0.89 | PARP1 (0.78) | PARP1PARP2PARP3TNKSADORA1 | |
| SCHEMBL16571627 | 0.89 | PARP1 (0.81) | PARP1PARP2PARP3TNKSADORA1 | |
| SCHEMBL30437593 | 0.89 | PARP1 (0.78) | PARP1PARP2PARP3TNKSADORA1 | |
| SCHEMBL30437265 | 0.89 | PARP1 (0.84) | PARP1PARP2PARP3TNKSADORA1 | |
| SCHEMBL16571718 | 0.89 | PARP1 (0.84) | PARP1PARP2PARP3TNKSADORA1 | |
| Hydrochloric Acid SCHEMBL16571458 | 0.88 | PARP1 (0.82) | PARP1PARP2PARP3TNKSADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49338-E1 | Phthalazinone derivatives and manufacturing process thereof | IDIENCE CO., LTD. (KR) | 2022-12-20 | — | — | US | claimed |
| US-9844550-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-12-19 | — | — | US | claimed |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2017-06-29 | — | — | US | claimed |
| US-9682973-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-06-20 | — | — | US | claimed |
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2016-08-04 | — | — | US | claimed |
| EP-3030557-A1 | A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | Ildong Pharm Co., Ltd. (KR) | 2016-06-15 | — | — | EP | claimed |
| WO-2015037939-A1 | A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | ILDONG PHARM CO., LTD. (KR) | 2015-03-19 | — | — | WO | claimed |
| EP-3030557-B1 | A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | IDIENCE CO LTD (KR) | 2023-05-31 | — | — | EP | disclosed |
| US-RE49338-E1 | Phthalazinone derivatives and manufacturing process thereof | IDIENCE CO., LTD. (KR) | 2022-12-20 | — | — | US | disclosed |
| US-20210323946-A1 | PROCESS FOR PREPARING A PHTHALAZINONE DERIVATIVE AND INTERMEDIATES THEREOF | IDIENCE CO., LTD. (KR) | 2021-10-21 | — | — | US | disclosed |
| US-9844550-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-12-19 | — | — | US | disclosed |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2017-06-29 | — | — | US | disclosed |
| US-9682973-B2 | Phtalazinone derivatives and manufacturing process thereof | ILDONG PHARM CO., LTD (KR) | 2017-06-20 | — | — | US | disclosed |
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | IL DONG HOLDINGS CO., LTD (KR) | 2016-08-04 | — | — | US | disclosed |
| CN-105793248-A | Novel phthalazinone derivatives and process for preparing the same | 日东制药株式会社 | 2016-07-20 | — | — | CN | disclosed |
| EP-3030557-A1 | A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | Ildong Pharm Co., Ltd. (KR) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015037939-A1 | A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF | ILDONG PHARM CO., LTD. (KR) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222003-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, PARP1 | PARP1 3/4885PARP2 12/4885PARP3 13/4885 |
| US-20170182045-A1 | Novel Phtalazinone Derivatives and Manufacturing Process Thereof | PARP15, PARP10, NUDT5 | PARP1 4/4885PARP2 12/4885PARP3 13/4885 |
| US-20210323946-A1 | PROCESS FOR PREPARING A PHTHALAZINONE DERIVATIVE AND INTERMEDIATES THEREOF | NISCH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DHPS | PARP1 1921/4885PARP2 2427/4885PARP3 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.